Vol. 5 No. 12 (2025)
Reimbursement Reviews

Darolutamide (Nubeqa)

decorative image of the issue cover

Published December 17, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • Canada’s Drug Agency reviewed Nubeqa to inform a recommendation for the public drug programs on whether it should be reimbursed in combination with androgen deprivation treatment for the treatment of metastatic castration-sensitive prostate cancer.
  • The sponsor is seeking reimbursement for this patient group in accordance with the criteria currently used for the reimbursement of apalutamide and enzalutamide in combination with androgen deprivation treatment.